[Form 4] Fulgent Genetics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Xie Jian, President and COO of Fulgent Genetics, Inc. (FLGT), reported the sale of 1,128 shares of the issuer's common stock on 09/03/2025 at a weighted-average sale price of $22.0267 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on 02/28/2022. After the reported sale, Mr. Xie beneficially owned 364,121 shares directly and held an additional 220,816 shares indirectly through The Hsieh Family Dynasty Trust, dated January 27, 2010. The Form 4 was executed by Paul Kim as attorney-in-fact.

Positive

• Transaction disclosed clearly: the sale is explicitly described as tax-withholding related to RSU vesting.
• Detailed price disclosure: weighted-average sale price ($22.0267) and price range ($21.92–$22.175) are provided.
• Continued significant holdings: reporting person retains 364,121 direct shares plus 220,816 indirect shares via trust.

Negative

• Reduction in direct holdings: 1,128 shares were sold, decreasing the reporting person's direct stake.
• Insider sale may be read negatively by some investors despite being for tax withholding purposes.

Insights

Corporate Governance Expert

TL;DR: Insider sale appears to be a routine tax-withholding disposition tied to RSU vesting, not a directional signal about company performance.

The filing documents a small, clearly labeled sale to cover tax liabilities from vested restricted stock units. The transaction is described as multiple sales aggregated to a weighted-average price and does not indicate additional derivative activity or a change in control. The report also discloses indirect holdings via a family trust with a disclaimer of beneficial interest, which is standard governance disclosure. Overall, this is a routine insider administrative transaction.

Securities Analyst

TL;DR: The sale of 1,128 shares is immaterial relative to total holdings and stems from RSU tax withholding.

The reported weighted-average sale price was $22.0267, and the explanatory footnote confirms the sale satisfied tax withholding from RSUs originally granted 02/28/2022. Post-transaction direct beneficial ownership remains at 364,121 shares, with 220,816 held indirectly by a family trust. No options or other derivative transactions were reported. This filing provides transparency but does not present new operational or financial information about the issuer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xie Jian

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		S		1,128(1)	D	$22.0267(2)	364,121	D
Common Stock								220,816	I	By Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022.

2. The shares were sold in multiple transactions at prices ranging from $21.92 to $22.175, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

3. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.

	/s/ Paul Kim as Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did FLGT insider Xie Jian report on Form 4?

He reported the sale of 1,128 shares on 09/03/2025 at a weighted-average price of $22.0267 to satisfy tax withholding from RSU vesting.

Why were the shares sold according to the filing?

The explanatory note states the shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on 02/28/2022.

How many shares does Xie Jian beneficially own after the transaction?

He beneficially owns 364,121 shares directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust.

What price range did the sales occur at?

Sales occurred at prices ranging from $21.92 to $22.175; the filing reports a weighted-average price of $22.0267.

Who signed the Form 4 filing?

The form was signed by Paul Kim as attorney-in-fact on 09/03/2025.